Contact
Biography
Dr Dong-Hyun Kim was appointed as an Assistant Professor in Analytical Bioscience in the School of Pharmacy, the University of Nottingham in October 2013. Prior to this position he conducted postdoctoral research on clinical metabolomics of trypanosomes in Glasgow Biomedical Research Centre at the University Glasgow (2010-2013) after four years in the School of Chemistry at the University of Manchester obtaining his PhD (2006-2010), which involved applications of analytical instruments for the investigation of cervical cancer. Also, he is a Director of the Centre for Analytical Bioscience and he oversees and manages the mass spectrometry facility. His role includes coordination of internal and external project work as well as fostering interdisciplinary applications of mass spectrometry-based analytical techniques. In addition, he was appointed as an Associate Director of Green Chemicals Beacon supported by the University of Nottingham 'Beacons of Excellence' (UoN cross-Faculty interdisciplinary initiative) where he leads Analytics and Omics Data Mining group.
Expertise Summary
Mass spectrometry applied to pharmaceutical, life and biomedical sciences research
i) Biomarker discovery of disease - global metabolite profiling using metabolomics and lipidomics methods
ii) Metabolic pathway profiling - targeted analysis of metabolites, stable isotope assisted analysis
iii) Ambient imaging of biological tissues by mass spectrometry
Teaching Summary
MPharm
1. Dyspepsia - Module convenor
2. Research Projects - Module convenor
3. Medical Diagnostics - Co-module convenor
Research Summary
Dr Dong-Hyun Kim's research career has focused on the advancement and application of mass spectrometry (MS)-based methods in order to investigate complex samples and matrices in life sciences and… read more
Selected Publications
JOHNSTON, K.*, KIM, D.-H.*, KERKHOVEN, E. J., BURCHMORE, R., BARRETT, M. P. and ACHCAR, F., 2019. Mapping the metabolism of five amino acids in bloodstream form Trypanosoma brucei using U-13C-labelled substrates and LC-MS Bioscience Reports. 39(5), BSR20181601. *Co-first authors SCHATSCHNEIDER, S., ABDELRAZIG, S., SAFO, L., HENSTRA, A. M., MILLAT, T., KIM, D.-H., WINZER, K., MINTON, N. P. and BARRETT, D. A., 2018. Quantitative Isotope-Dilution High-Resolution-Mass-Spectrometry Analysis of Multiple Intracellular Metabolites in Clostridium autoethanogenum with Uniformly 13C-Labeled Standards Derived from Spirulina Analytical Chemistry. 90(7), 4470–4477
Current Research
Dr Dong-Hyun Kim's research career has focused on the advancement and application of mass spectrometry (MS)-based methods in order to investigate complex samples and matrices in life sciences and physical sciences. He has been particularly interested in employing isotopically labelled compounds to enable accurate metabolic pathway analysis and to enhance the reproducibility and quantitation of MS-based methods including untargeted metabolite profiling and ambient surface analysis.
His research areas are:
• Biomarker of disease / drug discovery using MS-based global metabolite profiling
• Metabolic pathway profiling (targeted and stable isotope assisted analysis)
• Ambient imaging of biological tissues by mass spectrometry
• Absolute quantification using heavy atom labelled organism
• Metabolic flux analysis
His current research grants are:
• Targeting glioblastoma drug resistance through RNA methylation (The Brain Tumour Charity)
• Exploring alterations in amino acid metabolism as novel therapeutic targets in paediatric glial tumours using advanced metabolomics methods (Little Princess Trust Project Grant, CCLG Children's Cancer and Leukaemia Group)
• Hijacking plant immunity: winners and losers in dual pest and pathogen attacks on a shared host (BBRSC)
• Investigating anti-carcinogenic properties of Mezquite (UNICAS)
• Disrupting cancer metabolism to improve therapy for childhood ependymoma (Stoneygate Catalyst Award, Stoneygate Children's Brain Tumour Research Fund)
• Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers (Little Princess Trust Project Grant, CCLG Children's Cancer and Leukaemia Group)